We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Dialysis Patients Living at Higher Altitudes Have a Lower Rate of Death

By HospiMedica International staff writers
Posted on 19 Feb 2009
Dialysis patients living at altitudes higher than 1,200 meters have a 12-15% lower rate of death compared to those living near sea level, according to a new study.

Researchers at Brigham and Women's Hospital (Boston, MA, USA) examined a comprehensive U.S. More...
dialysis registry and identified 804,812 patients with end stage renal disease (ESRD) who initiated dialysis between 1995 and 2004, and who met the study entry requirements. Most patients resided below an altitude of 75 meters (40.5%) or between 75-610 meters (54.4%). Only 1.9% of incident dialysis patients lived between 1,200 and 1,800 meters, and 0.4% lived higher than 1,800 meters. Patients were stratified by the average elevation of their residential U.S. postal (zip) code.

The results showed that when compared with patients living at lower altitudes, the rate of death was reduced for patients living from 75-610 meters by 3%; from 600 to 1,200 meters by 7%; from 1,200 and 1,800 meters by 12% percent; and higher than 1,800 meters by 15%. Actuarial 5-year survival was 34.8% for patients living at or near sea level but was 42.7% among those living at an altitude higher than 1,800 meters. Patients in the highest elevation group experienced a 7.9% greater absolute or 22.7% greater relative 5-year survival. Median (midpoint) survival after initiation of dialysis was 3.1 years for those living lower than 75 meters, but was four years for those living at an altitude higher than 1,800 meters, a difference in median survival of 0.9 years between the two groups. While a decrease in age- and sex-standardized mortality at higher altitude was also observed in the general population, the magnitude of the risk reduction was half of that observed in the ESRD population. The study was published in the February 4, 2009, issue of the Journal of the American Medical Association (JAMA).

"…We found a graded reduction in mortality from any cause in ESRD patients residing at greater altitude, a finding that was not explained by differences in observed patient characteristics,” concluded lead author Wolfgang Winkelmayer, M.D., Sc.D., and colleagues. "The magnitude of this observation was markedly greater than the observed small reduction in mortality at higher altitude in the general population. We propose that hypoxia-inducible factors are persistent at high altitude in patients with ESRD and may confer protective effects.”

Related Links:
Brigham and Women's Hospital



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.